Centralized Envelope Comparative Immunogenicity Study

This project completed in June 2015.

The Centralized Envelope Comparative Immunogenicity Study is an HIV/AIDS vaccine development project that seeks to answer a central question that has blocked the development of a successful HIV vaccine: how can we design vaccine immunogens that address the broad genetic diversity of HIV? In this project, experimental immunogens were manufactured through an NIH contract, characterized by academic collaborators, and provided for testing in a Phase I clinical trial. The goal was to enable researchers to accelerate HIV vaccine development by reducing the need for multiple pre-clinical and clinical trials to optimize the immunogen design in order to achieve the broadest protection. The project was funded in 2009 by the Bill & Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery. The study involved the National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS, the Center for HIV/AIDS Vaccine Immunology at Duke University, the NIAID HIV Vaccine Trials Network and several other partners. In 2015, management responsibility was transferred from the FNIH to Duke University.

Goals

  • Prepare viral-vectored immunogens based on HIV Env protein and designed to induce a T cell response
  • Conduct a Phase I clinical trial to test their immunogenicity

Partners 

Public-Sector Partners:
National Institute of Allergy and Infectious Diseases (NIAID)*

Private-Sector Partners:
Bill & Melinda Gates Foundation*

Academic Partners:
Duke University Foundation

*Provided financial or in-kind support for this program.

FNIH Contacts

Stephanie James, Ph.D., Senior Vice President of Science; sjames@fnih.org